<code id='C17BC6EE9C'></code><style id='C17BC6EE9C'></style>
    • <acronym id='C17BC6EE9C'></acronym>
      <center id='C17BC6EE9C'><center id='C17BC6EE9C'><tfoot id='C17BC6EE9C'></tfoot></center><abbr id='C17BC6EE9C'><dir id='C17BC6EE9C'><tfoot id='C17BC6EE9C'></tfoot><noframes id='C17BC6EE9C'>

    • <optgroup id='C17BC6EE9C'><strike id='C17BC6EE9C'><sup id='C17BC6EE9C'></sup></strike><code id='C17BC6EE9C'></code></optgroup>
        1. <b id='C17BC6EE9C'><label id='C17BC6EE9C'><select id='C17BC6EE9C'><dt id='C17BC6EE9C'><span id='C17BC6EE9C'></span></dt></select></label></b><u id='C17BC6EE9C'></u>
          <i id='C17BC6EE9C'><strike id='C17BC6EE9C'><tt id='C17BC6EE9C'><pre id='C17BC6EE9C'></pre></tt></strike></i>

          Home / knowledge / explore

          explore


          explore

          author:entertainment    Page View:73
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In